Gastroenterology

Natural History and Selection
of Patients for Treatment of HBV

This CME/CE activity has reached its termination date and no longer offers continuing education credit. Please note that expired CME activities may not contain the most up-to-date information available.

Click here to view our current activities in Gastroenterology.

Natural History and Selection of Patients for Treatment of HBV

Download a PDF of the Syllabus

Home Study Version
Technical Requirements

To View Webcast, Click Here
(requires free Flash plug-in)

A FREE, Interactive 1-Hour CME/CE Audioconference

Discussion will include:

Epidemiology and natural history of hepatitis B infection, worldwide and in the United States.
Identification of risk factors for HBV infection and disease progression.
Screening and evaluation protocols.
Use and interpretation of serologic and molecular diagnostic assays and liver biopsy.
Rationale for selecting candidates for treatment, including those in special populations, based on risk factors for disease progression and published treatment guidelines.

DEVELOPMENT FACULTY
Adrian M. Di Bisceglie, MD, FACP Professor of Internal Medicine Chief of Hepatology Saint Louis University School of Medicine St. Louis, Missouri	Robert G. Gish, MD Medical Director Liver Transplant Program Chief, Division of Hepatology and Complex GI California Pacific Medical Center San Francisco, California
FACULTY
Nezam H. Afdhal, MD Chief of Hepatology Beth Israel Deaconess Medical Center Boston, Massachusetts Tse-Ling Fong, MD Associate Professor of Medicine Liver Transplantation Program University of Southern California Keck School of Medicine Los Angeles, California	Rajender Reddy, MD Professor of Medicine & Surgery Director of Hepatology Medical Director of Liver Transplantation University of Pennsylvania Medical Center Philadelphia, Pennsylvania Mark S. Sulkowski, MD Associate Professor of Medicine Johns Hopkins University School of Medicine Baltimore, Maryland

top

TARGET AUDIENCE

This CME/CE activity is designed for gastroenterologists, hepatologists, and other clinicians who care for patients with hepatitis B infection or those at increased risk for acquiring the infection.

ACTIVITY GOAL

The goal of this activity is to analyze the epidemiology, natural history, and screening and diagnostic procedures for assessing HBV infections and candidates for therapy.

LEARNING OBJECTIVES

Describe the epidemiology of HBV infection, including genotype distribution.
Identify patients at risk for HBV infection, including geographically-at-risk groups, injection drug users, HIV-positive patients, and healthcare workers.
Incorporate the latest developments in hepatitis B serologic and molecular testing for diagnosing acute and chronic HBV infection.
Distinguish between acute and chronic disease, and between active and inactive disease.
Utilize risk factors for disease progression and published treatment guidelines to select patients that are candidates for therapy.
Recognize and manage the long-term sequelae of untreated hepatitis B infection, including cirrhosis, decompensated liver disease, hepatocellular carcinoma, and systemic manifestations.

top

CME INFORMATION

Statement of Accreditation

Projects In Knowledge is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation

Projects In Knowledge designates this educational activity for a maximum of 1 Category 1 credit toward the AMA Physician's Recognition Award.

This independent CME activity is planned and implemented in accordance with the ACCME Essential Areas and Policies.

Physician Assistants

This program has been reviewed and is approved for a maximum of 1 hour of AAPA Category 1 (Preapproved) CME credit by the Physician Assistant Review Panel. Physician assistants should claim only those hours actually spent participating in the CME activity.

This program was planned in accordance with AAPA's CME Standards for Enduring Material and for Commercial support of Enduring Material Programs.

CE INFORMATION

This activity has been approved by the American Association of Critical-Care Nurses (AACN) for 1.0 contact hour. Provider #00012705.

Contract for Mutual Responsibility in CME/CE
Projects In Knowledge has developed the contract to demonstrate our commitment to providing the highest quality professional education to clinicians, and to help clinicians set educational goals to challenge and enhance their learning experience.
For more information on the contract, click here.

top

DISCLOSURE INFORMATION

The Disclosure Policy of Projects In Knowledge requires that presenters comply with the Standards for Commercial Support. All faculty are required to disclose any personal interest or relationship they or their spouse/partner have with the supporters of this activity or any commercial interest that is discussed in their presentation. Any discussions of unlabeled/unapproved uses of drugs or devices will also be disclosed in the course materials.

For complete prescribing information on the products discussed during this CME/CE activity, please see your current Physicians' Desk Reference (PDR).

Nezam H. Afdhal, MD, has received grant/research support from Bristol-Myers Squibb Company, Coley Pharmaceutical Group, Inc, Idenix Pharmaceuticals Inc, Idun Pharmaceuticals, Inc, InterMune Inc, Isis Pharmaceuticals, Inc, Ortho Biotech Products, LP, Prometheus Laboratories, Inc, Schering-Plough Corporation, United Therapeutics, and Valeant Pharmaceuticals International; is a consultant for EchoSens, Gilead Sciences, Inc, Idenix Pharmaceuticals, Inc, Isis Pharmaceuticals, Inc, Ortho Biotech Products, LP, Prometheus Laboratories Inc, Schering-Plough Corporation, and Valeant Pharmaceuticals International; and is on the speakers bureau of Gilead Sciences, Inc, Ortho Biotech Products, LP, and Schering-Plough Corporation.

Adrian M. Di Bisceglie, MD, FACP, has received grant/research support from Gilead Sciences, Inc, Roche Pharmaceuticals, and Schering-Plough Corporation; is a consultant for Abbott Laboratories, Bristol-Myers Squibb Company, Chiron Corporation, InterMune Inc, and SciClone Pharmaceuticals; is on the speakers bureau of Schering-Plough Corporation; is a member of advisory boards for Idenix Pharmaceuticals, Inc, MDS Nordion, Novartis Pharmaceuticals Corporation, and Vertex Pharmaceuticals Incorporated; and is a member of the Data Safety Monitoring Board for Schering-Plough Corporation.

Tse-Ling Fong, MD, has received grant/research support from Fujisawa Healthcare and Roche Pharmaceuticals; is a consultant for Amgen Inc and Roche Pharmaceuticals; and is on the speakers bureau of Roche Pharmaceuticals.

Robert. G. Gish, MD, has disclosed affiliations with Bayer Pharmaceutical Corporation (grant/research support, consultant, speakers bureau, and honoraria), Bristol-Myers Squibb Company (grant/research support, consultant, speakers bureau, and honoraria), Bristol-Myers Squibb Company Entecavir Global Advisory Panel (grant/research support, consultant, speakers bureau, and honoraria), Eximias Pharmaceutical Corporation (grant/research support, consultant, speakers bureau, and honoraria), Gilead Sciences Inc (grant/research support, consultant, speakers bureau, and honoraria), GlaxoSmithKline (grant/research support, consultant, speakers bureau, and honoraria), Human Genome Sciences (consultant), InterMune Inc (grant/research support, consultant, speakers bureau, and honoraria), Ortho Biotech Products, LP (grant/research support, consultant, speakers bureau, and honoraria), Roche Pharmaceuticals (grant/research support, consultant, speakers bureau, and honoraria), Schering-Plough Corporation (grant/research support, consultant, speakers bureau, and honoraria), SciClone Pharmaceuticals (grant/research support, consultant, speakers bureau, and honoraria), United Therapeutics (grant/research support), Valeant Pharmaceuticals International (grant/research support, consultant, speakers bureau, and honoraria), XTL Biopharmaceuticals Ltd (grant/research support).

Rajender Reddy, MD, has received grant/research support from Roche Pharmaceuticals, Valeant Pharmaceuticals International, and Wyeth Pharmaceuticals; is a consultant for Amgen Inc (ad hoc) and Roche Pharmaceuticals; is on the speakers bureau of Gilead Sciences, Inc, and Roche Pharmaceuticals; and has received honoraria from Amgen Inc, Gilead Sciences, Inc, and Roche Pharmaceuticals.

Mark S. Sulkowski, MD, has received grant/research support from Akros Pharma Inc, Human Genome Sciences, Idenix Pharmaceuticals Inc, Roche Pharmaceuticals, Schering-Plough Corporation, Valeant Pharmaceuticals International, and Vertex Pharmaceuticals Incorporated; is on the advisory board of Boehringer-Ingelheim Pharmaceuticals, Inc, Bristol-Myers Squibb Company, Human Genome Sciences, Ortho Biotech Products, LP, Roche Pharmaceuticals, Schering-Plough Corporation, and Valeant Pharmaceuticals International; and is on the speakers bureau of Abbott Laboratories, Ortho Biotech Products, LP, Roche Pharmaceuticals, and Schering-Plough Corporation.

Projects In Knowledge's staff members have no significant relationships to disclose.

Conflicts of interest are thoroughly vetted by the Executive Committee of Projects In Knowledge. All conflicts are resolved prior to the beginning of the activity by the Trust In Knowledge peer review process.

The opinions expressed in this activity are those of the faculty and do not necessarily reflect those of Projects In Knowledge.

This CME/CE activity is provided by Projects In Knowledge solely as an educational service. Specific patient care decisions are the responsibility of the clinician caring for the patient.

This independent CME/CE activity is supported by an educational grant from
Bristol-Myers Squibb Company.

top

1716